Editas Medicine Inc. - Common Stock
This usually takes 2-5 minutes, but may take up to 15 minutes
It creates gene-editing treatments to fix genetic problems in diseases like sickle cell anemia. Doctors and patients use these therapies because they target the root cause of illnesses. The company makes money by partnering with other firms, getting payments for research milestones, and aiming to sell approved drugs in the future.
It creates gene-editing treatments to fix genetic problems in diseases like sickle cell anemia. Doctors and patients use these therapies because they target the root cause of illnesses. The company makes money by partnering with other firms, getting payments for research milestones, and aiming to sell approved drugs in the future.
This company operates in the biotechnology sector, focusing on gene editing to treat genetic disorders. It competes with other firms developing similar therapies, often through partnerships with larger pharmaceutical companies. The industry is driven by innovation and regulatory approvals, with high
This company operates in the biotechnology sector, focusing on gene editing to treat genetic disorders. It competes with other firms developing similar therapies, often through partnerships with larger pharmaceutical companies. The industry is driven by innovation and regulatory approvals, with high
